Pegylated interferon alfa-2b as treatment of solid tumors

被引：3
|
作者：
Ronald M. Bukowski
机构：
来源：
Current Oncology Reports | 2003年 / 5卷 / 2期
关键词：
Melanoma; Renal Cell Carcinoma; Clin Oncol; Sustained Virologic Response; Maximum Tolerate Dose;
D O I：
10.1007/s11912-003-0094-7
中图分类号：
学科分类号：
摘要：
PEG-IFN á-2b is active in patients with metastatic RCC and melanoma and is tolerated well at doses up to 6.0 μg/kg/wk. This trial provides a rationale for further studies using this pegylated cytokine alone or in combination with such agents as interleukin (IL)-2.
引用
收藏
页码：87 / 88
页数：1
相关论文
共 50 条
  • [31] Induction of Autoimmune Hepatitis by Pegylated Interferon Alfa-2b in Chronic Hepatitis C
    Loerke, Julia
    Erhardt, Andreas
    Haeussinger, Dieter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (12) : A20 - A20
  • [32] Treatment of acute hepatitis C with interferon alfa-2b
    Jaeckel, E
    Cornberg, M
    Wedemeyer, H
    Santantonio, T
    Mayer, J
    Zankel, M
    Pastore, G
    Dietrich, M
    Trautwein, C
    Manns, MP
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20): : 1452 - 1457
  • [33] 48 Weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achieving HBeAg seroconversion in chronic hepatitis B infection
    Lai, Lawrence S. W.
    Fung, Tang-Tat
    Lai, Sik-To
    Yiu, Jak
    Lam, Polly
    Zhang, Hai-Ying
    Wong, Wai-Man
    Lo, Chung-Mau
    Fan, Sheung-Tat
    Hui, Chee-Kin
    Leung, Nancy
    Lau, George K. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A90 - A90
  • [34] Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients
    Taliani, G
    Gemignani, G
    Ferrari, C
    Aceti, A
    Bartolozzi, D
    Blanc, PL
    Capanni, M
    Esperti, F
    Forte, P
    Guadagnino, V
    Mari, T
    Marino, N
    Milani, S
    Pasquazzi, C
    Rosina, F
    Tacconi, D
    Toti, M
    Zignego, AL
    Messerini, L
    Stroffolini, T
    GASTROENTEROLOGY, 2006, 130 (04) : 1098 - 1106
  • [35] Pegylation of recombinant interferon alfa-2b does not alter protein conformation and the pegylated interferon alfa-2b demonstrates equivalent in vitro biological potency to Intron-A.
    Grace, M
    Youngster, S
    Gitlin, G
    Sydor, W
    Xie, L
    Westreich, LN
    Jacobs, S
    Brassard, D
    Bausch, J
    Bordens, R
    HEPATOLOGY, 2001, 34 (04) : 420A - 420A
  • [36] Pegylated interferon alfa-2b plus ribavirin in the re-treatment of interferon-ribavirin non responder patients
    Taliani, Gloria
    Gemignani, Giulia
    Ferrari, Carlo
    Aceti, Antonio
    Bartolozzi, Dario
    Blanc, Pier Luigi
    Capanni, Marco
    Esperti, Francesco
    Forte, Paolo
    Guadagnino, Vincenzo
    Mari, Terenzio
    Marino, Nicoletta
    Milani, Stefano
    Pasquazzi, Caterina
    Tacconi, Danilo
    Toti, Mario
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A124 - A125
  • [37] Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks
    Sarrazin, Christoph
    Schwendy, Susanne
    Moeller, Bernd
    Dikopoulos, Nektarios
    Buggisch, Peter
    Encke, Jens
    Teuber, Gerlinde
    Goeser, Tobias
    Thimme, Robert
    Klinker, Hartwig
    Boecher, Wulf O.
    Schulte-Frohlinde, Ewert
    Prinzing, Renate
    Herrmann, Eva
    Zeuzem, Stefan
    Berg, Thomas
    GASTROENTEROLOGY, 2011, 141 (05) : 1656 - 1664
  • [38] Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
    Al Ali, Jaber
    Owayed, Salem
    Al-Qabandi, Wafa'a
    Husain, Khaled
    Hasan, Fuad
    ANNALS OF HEPATOLOGY, 2010, 9 (02) : 156 - 160
  • [39] Comparison of pegylated interferon alfa-2a and alfa-2b in combination with ribavirin in obese patients with chronic hepatitis
    Moore, CH
    Angtuaco, TL
    Lindsey, JL
    Nelson, SD
    Malik, AH
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S109 - S109
  • [40] Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
    Huang, Yi-Wen
    Hsu, Chao-Wei
    Lu, Sheng-Nan
    Yu, Ming-Lung
    Su, Chien-Wei
    Su, Wei-Wen
    Chien, Rong-Nan
    Hsu, Ching-Sheng
    Hsu, Shih-Jer
    Lai, Hsueh-Chou
    Qin, Albert
    Tseng, Kuan-Chiao
    Chen, Pei-Jer
    HEPATOLOGY INTERNATIONAL, 2020, 14 (06) : 997 - 1008
12345